Higher-Dose Nusinersen Meets Primary End Point in Phase 2/3 DEVOTE Study for Spinal Muscular Atrophy
Nusinersen May Improve Fatiguability in SMA, but More Research Is Needed
Virtual Reality Is a Game-Changer During Blood Draws for Pediatric Patients With SMA
New Motor Milestones Achieved or Sustained With Apitegromab in Nonambulatory SMA
The introduction of 3 FDA-approved therapies for spinal muscular atrophy is enabling clinicians to treat the disease completely different from how it was handled in the past.
Dr Vamshi Rao Discusses Possible Future Guidelines for SMA Care
Dr Vamshi Rao Discusses the Future of Combination Therapy in SMA
Dr Vamshi Rao Discusses Safety, Efficacy of SMA Treatments
Dr Vamshi Rao Discusses How COVID-19 Impacted SMA Treatment Access
Dr Vamshi Rao Discusses How New Therapies Are Changing Physician Perceptions on SMA Prognosis
Dr Jill Jarecki Discusses Whether Gender Affects SMA Severity
Dr Jill Jarecki Discusses the Early SMA Treatment for Infants
Drs Mary Schroth and Jill Jarecki Discuss Treatments for All SMA Types
Dr Jill Jarecki Discusses the Current Pipeline for SMA Therapies
Dr Mary Schroth Discusses At-Home Treatment Options for Patients With SMA
Qualitative Study Explores Caregiver Experiences in SMA Treatment
Real-World Data Show Most Nusinersen Doses Administered on Time
Improving SMA HRQOL Must Address Patient and Caregiver Well-being